Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722198 | 0.89 | PDPK1 (0.77) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL6852601 | 0.83 | LOXL2 (0.67) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL17704291 | 0.80 | PDPK1 (0.65) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL19219079 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL3885226 | 0.78 | LOXL2 (0.66) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL466424 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL4589649 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL466426 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL21791658 | 0.78 | LOXL2 (0.71) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL5147639 | 0.78 | PDPK1 (0.91) | PDPK1LOXL2ADRB2CYP2A6ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448940-B | For the medical composition of glaucomatous treatment or prevention | UBE INDUSTRIES, LTD. (JP) | 2015-10-21 | — | — | CN | claimed |
| CN-101970410-B | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2014-06-25 | — | — | CN | claimed |
| CN-102548985-A | Substituted carbonyl compounds | UBE INDUSTRIES | 2012-07-04 | — | — | CN | claimed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | claimed |
| CN-101970410-A | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2011-02-09 | — | — | CN | claimed |
| EP-1647545-A1 | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2006-04-19 | — | — | EP | claimed |
| EP-1005493-B1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-11-02 | — | — | EP | claimed |
| CN-1118476-C | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2003-08-20 | — | — | CN | claimed |
| US-6489364-B2 | FROM L-MANNONIC-GAMMA-LACTONE INTERMEDIATES; FOR PROPHYLAXIS OF HIV/AIDS HIV | MEDIVIR AB (SE) | 2002-12-03 | — | — | US | claimed |
| US-20010044547-A1 | Antiviral protease inhibitors | MEDIVIR AB | 2001-11-22 | — | — | US | claimed |
| US-6291687-B1 | USED ASPARTYL PROTEASE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | MEDIVIR AB (SE) | 2001-09-18 | — | — | US | claimed |
| CN-1258301-A | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2000-06-28 | — | — | CN | claimed |
| EP-1005493-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2000-06-07 | — | — | EP | claimed |
| WO-1998045330-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 1998-10-15 | — | — | WO | claimed |
| CN-106458904-B | N-substituted sulfonamide compound and process for producing the same | 宇部兴产株式会社 | 2021-12-03 | — | — | CN | disclosed |
| CN-106458903-B | Method for producing heteroaromatic sulfonamide compound | 宇部兴产株式会社 | 2021-02-05 | — | — | CN | disclosed |
| US-10774072-B2 | Crystal of N-substituted sulfonamide compound | UBE INDUSTRIES, LTD. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-6420418-B1 | INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| WO-2001012183-A1 | HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-0439556-A4 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | — | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774072-B2 | Crystal of N-substituted sulfonamide compound | STS, SLC10A6, CA3 | PDPK1 4775/4885LOXL2 3896/4885ADRB2 4371/4885 |
| US-20010044547-A1 | Antiviral protease inhibitors | PEPD, PREP, CTSL | PDPK1 3581/4885LOXL2 1281/4885ADRB2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.